Dimitrios Kirmizis

Dimitrios Kirmizis

Auto-generated profile, based on publicly available information

Dimitrios Kirmizis

Department of Nephrology, Colchester General Hospital, Essex, UK

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in International Journal of Nanomedicine
Verified
Journal Article
Open access
DKDimitrios Kirmizis
Dimitrios Kirmizis
SLStergios Logothetidis
Stergios Logothetidis
Peer reviewed article authored by (Dimitrios Kirmizis, Stergios Logothetidis). Read article or submit your manuscript for publishing.

1 December 2006 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
LBLuigi Bisceglia
Luigi Bisceglia
GCGiuseppina Cerullo
Giuseppina Cerullo
PFPaola Forabosco
Paola Forabosco
DTDiletta Domenica Torres
Diletta Domenica Torres
FSFrancesco Scolari
Francesco Scolari
FSFrancesco Paolo Schena
Francesco Paolo Schena

1 January 2003 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
APAikaterini Papagianni
Aikaterini Papagianni
MKMichalis Kalovoulos
Michalis Kalovoulos
DKDimitrios Kirmizis
Dimitrios Kirmizis
AVAndreas Vainas
Andreas Vainas
ABAnna‐Maria Belechri
Anna‐Maria Belechri
DMDimitrios Memmos
Dimitrios Memmos
Background. Recently emerging evidence suggests that endothelial adhesion molecules may participate in atherogenesis. The aim of the present report was to investigate the probable association of circulating ICAM‐1, VCAM‐1 and E‐selectin with atherosclerotic disease in chronic haemodialysis (HD) patients. Methods. One hundred and twelve HD patients and 50 age‐ and sex‐matched healthy normotensive controls participated in the study. Atherosclerotic disease in both groups was assessed by measuring intima–media thickness (IMT) and plaque score of the common carotid arteries using an ultrasound scanner. In addition, in a follow‐up study, the survival of 81 patients after a mean period of 26 months was analysed in relation to ICAM‐1 and VCAM‐1 levels. Results. IMT and plaque score were significantly higher in HD patients compared with control subjects (P<0.001 and P<0.0001, respectively). The above ultrasonographic indices were correlated with age both in controls (P=0.0001 and P=0.002, respectively) and HD patients (P=0.0001 and P=0.0001, respectively). A significant relationship was observed between IMT and systolic blood pressure (BP) both in controls and in HD patients (P=0.002 and P=0.01, respectively). In HD patients, plaque score was also correlated with systolic BP (P=0.02). In HD patients, IMT and plaque score were correlated significantly with log CRP values (P=0.01 and P=0.01, respectively). Multivariate analysis showed that log CRP values were a strong independent contributor to plaque score (P=0.01). IMT was significantly correlated with ICAM‐1 and VCAM‐1 concentrations (P=0.0001 and P=0.003, respectively). Multivariate analysis showed that ICAM‐1 concentrations were a strong independent correlate of IMT (P=0.001). E‐selectin concentrations did not show any relation with IMT or plaque score. During the follow‐up period, 13 of the 81 patients died. Survival analyses showed that patients with increased ICAM‐1 had a shorter survival than patients with normal ICAM‐1 values and that serum ICAM‐1 levels were a strong predictor of death. Conclusions. In HD patients, carotid atherosclerosis is associated with inflammation and circulating levels of soluble adhesion molecules ICAM‐1 and VCAM‐1. The correlations between serum ICAM‐1 and IMT and ICAM‐1 and survival may indicate that this molecule could be a marker of a process that contributes to the high mortality of HD patients.

11 August 2020 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
CBCarlo Basile
Carlo Basile
ADAndrew Davenport
Andrew Davenport
SMSandip Mitra
Sandip Mitra
APAvishek Pal
Avishek Pal
DSDimitrios Stamatialis
Dimitrios Stamatialis
DKDimitrios Kirmizis
Dimitrios Kirmizis

2 December 2010 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
DKDimitrios Kirmizis
Dimitrios Kirmizis
APAikaterini Papagianni
Aikaterini Papagianni
ABAnna-Maria Belechri
Anna-Maria Belechri
DMDimitrios Memmos
Dimitrios Memmos
Background. In the present prospective, controlled, observational cohort study, we investigated the effects of the use of a vitamin E-coated membrane dialyser (VEM) on markers of chronic inflammation, oxidative stress and endothelial cell apoptosis in end-stage renal disease (ESRD) patients on chronic haemodialysis (HD), as long as evidence of their effects on these pathogenetic routes are inconclusive as yet, despite their use for the last several years. Methods. Thirty-five stable ESRD patients underwent HD with the use of VEM for 6 months. Another 25 age- and sex-matched ESRD patients, being dialysed with conventional dialysers, served as controls. In both patient groups, beyond complete haematology and biochemistry work-up, serum CRP, apolipoproteins A1 and B, lipoprotein (a) (Lp(a)), hsIL-6, MCP-1, sICAM-1, sVCAM-1, sE-selectin, sFas and sFasL as well as plasma oxLDL, TBARS and TAS levels were determined at baseline and at 6 months of the study. Results. In the VEM group at 6 months, a significant reduction in CRP (P = 0.004), IL-6 (P = 0.004) and sICAM-1 (P = 0.04) levels was observed compared with baseline, along with a remarkable change in all markers of oxidative stress, i.e. increase in TAS (P = 0.005) and decrease in TBARS (P = 0.04) and oxLDL (P < 0.001). No significant changes were noted in the other parameters studied in the VEM group or in any parameter studied in the controls. Between the groups, significant differences were found in the change of CRP (P = 0.001), sICAM-1 (P = 0.03) and oxLDL (P = 0.04) compared with baseline. Conclusions. HD with the use of VEM resulted in a significant reduction in inflammation and oxidative stress markers. Larger prospective randomized studies will need to confirm the findings of the present observational study.

1 January 2004 in Renal Failure
Verified
Journal Article
Closed access
EAEfstathios Alexopoulos
Efstathios Alexopoulos
MSMaria Stangou
Maria Stangou
APAphroditi Pantzaki
Aphroditi Pantzaki
DKDimitrios Kirmizis
Dimitrios Kirmizis
DMDirector Dimitrios Memmos
Director Dimitrios Memmos
M.M.D.
M.D.
Background. The effect of a “very low dose” of purified omega‐3 fatty acids (PFA) in the progression of severe IgA nephropathy (IgAN) was tested, in a randomized, prospective, controlled trial. Methods. Fourteen patients were assigned to receive a “very low dose” of PFA (0.85 g EPA and 0.57 g PHA) and 14 patients were treated symptomatically and used as controls. Both groups were similar in terms of serum creatinine (Scr) and glomerular filtration rate (GFR) at baseline. Patients were treated for 4 years. The primary end‐points were an increase of 50% or more in Scr or a decrease of 50% or more in GFR at the end of the study. Results. During treatment, 1 patient (7%) in the PFA group and 6 (43%) in the control group had an increase of 50% or more in their Scr (p < 0.01). Also, 1 patient (7%) in the PFA group and 7 (50%) in the control group had a decrease of 50% or more in GFR (p < 0.007). The mean annual change in Scr was 0.2 mg/dL in the PFA group and 1.0 mg/dL in the control group (p < 0.01). The mean ...